T2 Biosystems (NASDAQ:TTOO) Receives Daily News Sentiment Rating of 0.10

News stories about T2 Biosystems (NASDAQ:TTOO) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. T2 Biosystems earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 47.0234137405991 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

Shares of T2 Biosystems (NASDAQ TTOO) traded down $0.22 during midday trading on Monday, hitting $5.20. 250,800 shares of the stock traded hands, compared to its average volume of 403,378. The company has a debt-to-equity ratio of 2.25, a current ratio of 5.40 and a quick ratio of 5.28. The stock has a market cap of $186.29, a PE ratio of -2.74 and a beta of 1.48. T2 Biosystems has a 52-week low of $2.50 and a 52-week high of $6.99.

T2 Biosystems (NASDAQ:TTOO) last issued its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.04. The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $1.10 million. T2 Biosystems had a negative net margin of 1,497.70% and a negative return on equity of 244.82%. The firm’s revenue was up 2.8% compared to the same quarter last year. equities analysts forecast that T2 Biosystems will post -1.85 EPS for the current fiscal year.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of T2 Biosystems from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of T2 Biosystems in a research note on Friday, November 3rd. Finally, Canaccord Genuity restated a “buy” rating and set a $6.00 target price on shares of T2 Biosystems in a research note on Monday, October 30th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. T2 Biosystems presently has a consensus rating of “Hold” and a consensus target price of $6.54.

ILLEGAL ACTIVITY NOTICE: “T2 Biosystems (NASDAQ:TTOO) Receives Daily News Sentiment Rating of 0.10” was published by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/t2-biosystems-ttoo-earning-somewhat-positive-press-coverage-study-shows/1818884.html.

About T2 Biosystems

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Insider Buying and Selling by Quarter for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.